London, Ontario, Canada, 06 January, 2026 – KGK Science Inc., a leading full-service premium contract research organization (CRO) and regulatory consulting firm, today announced the publication of a randomized, triple-blind, placebo-controlled clinical trial conducted in collaboration with Unigen, Inc. The study has been published in the peer-reviewed journal Food Science & Nutrition.
The trial evaluated Maizinol®, a standardized nutraceutical ingredient developed by Unigen, in adults experiencing sleep disturbances. Objective sleep metrics were captured using validated sleep monitoring tools, alongside standardized questionnaires to assess subjective sleep outcomes, strengthening the clinical relevance of the findings.
The study reports statistical significance in three primary outcomes (baseline to Day 28): total sleep time, REM sleep, and light sleep. There was also statistical significance in improvement in four secondary outcomes (baseline to Day 14): REM sleep, awake duration (mins), awakenings > 3 mins, and sleep efficiency.
“This publication reflects the capabilities at KGK Science for doing rigorous studies involved in assessing sleep while leveraging the latest trends in virtual trials. This customized trial design allowed us to monitor participants while they were being recorded in the confines of their own homes without their need to report to a 24-hr sleep clinic and overnight stays,” said Najla Guthrie, President and CEO of KGK Science. “It represents a real game-changer for conducting sleep studies and has become one of our new arsenals of expertise. Dreaming up ways to substantiate claims with a sleep study can be challenging, but the end result can be very rewarding for those who follow through.”
The publication reinforces the role of independent clinical validation in substantiating nutraceutical claims and advancing innovation in sleep health.
The full study is available in Food Science & Nutrition.
For further information about the clinical study, please contact:
Anusri Nair
Marketing Manager
KGK Science Inc.
Email: anair@kgkscience.com
Website: www.kgkscience.com
About KGK Science
KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on nutraceutical and emerging health care products. Founded in 1997, the business has successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies to move products into global markets. KGK’s other existing service lines include expert regulatory support and compliance solutions, participant recruitment, research support services and consulting services. Furthermore, the company has produced over 150 publications, executed over 400 clinical trials across more than 40 indications, amassed 40,000 participants in its database and collected 10 million data points. For additional information, please visit kgkscience.com.
About Unigen, Inc.
Unigen discovers, develops, and manufactures proprietary natural-product active ingredients for dietary supplements, cosmetic and personal care products, prescription medical food and botanical drug products. The Company discovers its ingredients through its high throughput screening PhytoLogix® approach applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits.
Mechanism of action, safety and efficacy are documented with extensive preclinical in vitro and in vivo testing and by human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply alliances with commercial partners engaged in the manufacture, distribution, and marketing of end-products in each of Unigen’s target markets.
